July 28 (Reuters) - Britain's GSK (GSK.L), opens new tab and China's Jiangsu Hengrui Pharmaceuticals (600276.SS), opens new tab have agreed on a $500 million deal to develop up to a dozen new ...
GlaxoSmithKline (GSK) will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology, and inflammation (RI&I) as well as oncology, through a collaboration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback